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Abstract
Background: Enhanced supraspinal glutamate levels following nerve injury are associated with
pathophysiological mechanisms responsible for neuropathic pain. Chronic pain can interfere with specific brain
areas involved in glutamate-dependent neuropsychological processes, such as cognition, memory, and
decision-making. The medial prefrontal cortex (mPFC) is thought to play a critical role in pain-related
depression and anxiety, which are frequent co-morbidities of chronic pain. Using an animal model of spared
nerve injury (SNI) of the sciatic nerve, we assess bio-molecular modifications in glutamatergic synapses in the
mPFC that underlie neuropathic pain-induced plastic changes at 30 days post-surgery. Moreover, we examine
the effects of palmitoylethanolamide (PEA) administration on pain-related behaviours, as well as the cortical
biochemical and morphological changes that occur in SNI animals.
Results: At 1 month, SNI was associated with mechanical and thermal hypersensitivity, as well as depression-like
behaviour, cognitive impairments, and obsessive-compulsive activities. Moreover, we observed an overall
glutamate synapse modification in the mPFC, characterized by changes in synaptic density proteins and amino
acid levels. Finally, with regard to the resolution of pain and depressive-like syndrome in SNI mice, PEA restored
the glutamatergic synapse proteins and changes in amino acid release.
Conclusions: Given the potential role of the mPFC in pain mechanisms, our findings may provide novel
insights into neuropathic pain forebrain processes and indicate PEA as a new pharmacological tool to treat
neuropathic pain and the related negative affective states.
Background
Accumulating evidence suggests that dysfunction of
the glutamate system is correlated with the patho-
physiological mechanisms responsible for chronic pain
development or maintenance. Neuropathic or inflam-
matory injury triggers structural and functional changes in
the peripheral or central sensory circuits, resulting in
altered nociceptive signal processes, such as spontaneous
pain, allodynia, and hyperalgesia [1–4]. Chronic pain can
interfere with specific brain areas involved in glutamate-
dependent neuropsychological features, such as cognition,
memory, and decision-making [5, 6]. Enhanced glutam-
ate release and over-activation of glutamate receptors
following nerve injury has been observed in limbic
and cortical areas involved in pain-related responses,
including the anterior cingulate cortex (ACC), insular
cortex, and prelimbic and infralimbic (PL-IL) cortices
[7, 8]. Moreover, the activation of genes involved in
glutamate-mediated cellular signalling, via N-methyl-
D-aspartate (NMDA) or metabotropic glutamate
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receptors (mGluRs), has been described in cortical
areas under chronic pain conditions [9–11]. In par-
ticular, the medial prefrontal cortex (mPFC) is thought
to play a key role in pain-related depression and anx-
iety, which are frequent co-morbidities of chronic pain
[12, 13]. In fact, neural reorganization and changes in
neurotrophic or excitatory factors have been demon-
strated in the mPFC during neuropathic pain [14, 7].
PL-IL cortex corresponds to the dorsal-lateral pre-
frontal cortex in primates. It plays a crucial role in
pain processing and pathological pain deeply affects
its synaptic organization [7, 8, 14]. NMDA-induced
changes in dendritic plasticity has been shown in the
PL-IL cortex of neuropathic rats [15], whereas cortex
deactivation has been shown in rodents with persistent
inflammatory pain [16].
The endocannabinoid (eCB) system has been involved
in the pathogenesis of neuropathic pain [17–19]. In
addition, functional cross-talk between the endocannabino
id/endovanilloid and glutamatergic systems in antinocicep
tion as well as in psychotic disorders has been identified
[20–22]. Endogenous levels of eCB ligands change dur-
ing neuropathic pain in several regions of ascending
and descending pain pathways [23, 24]. In addition to
the classical eCBs, endocannabinoid-related N-acyletha-
nolamines, such as palmitoylethanolamide (PEA) and
oleoylethanolamide (OEA), have been shown to partici-
pate in pain mechanisms [25, 19]. In particular, PEA,
which is abundant in the central nervous system (CNS)
in physiological conditions, has been shown to be in-
volved in neuroprotective mechanisms activated under
several pathological states, including neuropathic pain
[26–28]. PEA is an endogenous anti-inflammatory me-
diator with pleiotropic effects due to the complex
mechanisms of action that have not been clarified. Our
previous studies, as well as those of others, have dem-
onstrated that chronic administration of PEA reduces
pain behaviours and counteracts spinal neuronal hyper
excitability in murine models of persistent pain [29, 2].
This study aimed to investigate bio-molecular modi-
fications in glutamate synapses of the mPFC that
underlie neuropathic pain-induced plastic changes in
an animal model of spared nerve injury (SNI) of the
sciatic nerve at 30 days post-surgery. We evaluated (i)
pain behaviours and the affective-cognitive impair-
ments associated with persistent peripheral neur-
opathy, (ii) bio-molecular changes occurring in the
proteins in mPFC synaptosomal fractions of SNI mice,
(iii) changes in levels of amino acids and acylethanola-
mines (PEA and oleoylethanolamide, OEA) in the
mPFC of SNI mice, and (iv) the effects of PEA admin-
istration on pain-related behaviours, as well as cortical
biochemical and morphological changes in SNI
animals.
Methods
Animals
Male CD-1 mice (30–35 gr) were housed 3 per cage
under controlled conditions (12:12 h light/dark cycle;
room temperature 20–22 °C, humidity 55–60 %) with
chow and tap water were available ad libitum. The ex-
perimental procedures were permitted by the Animal
Ethics Committee of the Second University of Naples.
Animal care was in observance with the IASP and
European Community (E.C. L358/1 18/ 12/86) guide-
lines on the use and protection of animals in experi-
mental research. All efforts were made to reduce
animal suffering and the number of animals used.
Spared Nerve Injury (SNI)
Neuropathy condition was induced according to Decos-
tered and Woolf method [30]. Mice were anesthetized
[ketamine (60 mg/kg) + xylazine (10 mg/kg)] and the sci-
atic nerve was exposed. The tibial and common peroneal
nerves were ligated and then transected, leaving the
sural nerve intact. Sham animals were anaesthetized and
the sciatic nerve was exposed, but not transected.
Pain behaviour
Plantar test
Thermal hyperalgesia was evaluated using the plantar
test (Ugo Basile). Mice were placed in clear Plexiglas
chambers; a mobile infrared radiant heat source was
focused under the plantar surface of the hind paws. La-
tency to paw withdrawal was determined by a timer.
The stimulus intensity was preset to obtain a paw with-
drawal latency ranging from 9 to 11 s. Withdrawal
threshold of the hind paws was defined as the mean of
three measurements. Dynamic Aesthesiometer. Mech-
anical allodynia was evaluated using the Dynamic Plan-
tar Aesthesiometer (Ugo Basile). This equipment
employs a single non-flexible filament (0.5-mm diam-
eter) to apply an increasing force to the plantar surface
of the mouse hind paw. Animals were placed in a cage
with a wire mesh floor and allowed to acclimatize be-
fore testing. The filament was applied to the plantar
area (plantar territory of the sural nerve) of the hind
paw and it began to exert an increasing upward force,
reaching a maximum of 30 g in 10 s, until the paw was
withdrawn. The withdrawal threshold was defined as
the force, in grams, at which the mouse withdrew its
paw. Withdrawal thresholds of ipsilateral and contralat-
eral paws were determined three times, and the
reported value is the mean of the three evaluations.
Pain behaviors were evaluated following PEA or OEA
(10 mg/kg, i.p.) repeated treatment (15 days) in sham
or SNI mice (up to 30 days). In a separate set of experi-
ments, sham and SNI mice were used for the assess-
ment of mechanical allodynia 30 days after surgery
Guida et al. Molecular Brain  (2015) 8:47 Page 2 of 15
before and after a single intra-PL-IL cortex microinjec-
tion of 200 nL of vehicle (0.5 % DMSO in artificial
cerebrospinal fluid, ACSF, in mM: 125.0 NaCl, 2.6 KCl,
2.5 NaH2PO4, 1.3 CaCl2, 0.9 MgCl2, 21.0 NaHCO3,
and 3.5 glucose, oxygenated and equilibrated to
pH 7.4), or PEA or OEA (6 nmol/mouse). The surgical
preparation for intra-PL-IL cortex administration was
performed the day before the experiment through a 20-
gauge stainless steel guide cannula stereotaxically low-
ered, by applying coordinates from the atlas of Paxinos
and Watson (1986) (AP: 1.4 mm, L: 0.5 mm from
bregma, V: 3 mm below the dura) [31]. The drugs doses
were chosen based on our previous studies [2, 25].
Tail suspension
Animals were suspended by the tail on a horizontal bar
(50 cm from the floor) using adhesive tape placed 4 cm
from the tip of the tail. The duration of immobility was
recorded in seconds over a period of 6 min of habitu-
ation. Immobility time was defined as the absence of
escape-directed behaviour.
Object recognition
The experiment started with the habituation period, dur-
ing which mice were allowed to freely explore for 1 h
the apparatus which consists of a rectangular open box
(40 × 30 × 30 cm width × length × height) made of grey
polyvinyl chloride (PVC) illuminated by a dim light. The
day after each mouse was allowed to explore two identi-
cal objects positioned in the back left and right corners
for 5 min (acquisition). A camera recorded the time
spent on exploration of each object. In the test trial,
which was carried out for 2 h after the acquisition, one
of the two objects was replaced with a new different ob-
ject. The time spent exploring the object was the time
the mouse spent with its nose directed, and within 1 cm,
from the object. The behaviour of mice was analyzed by
an observer blind to the treatment. Data were expressed
as percentage of recognition index (RI %), which was
calculated as the percentage of the time spent exploring
the novel object / time spent exploring the novel object
+ time spent exploring the familiar object × 100.
Marble-burying
Mice were individually placed in a cage (21 × 38 × 14 cm
length x width x height) containing 5 cm layer of saw-
dust bedding and fifteen glass marbles (1.5 cm in diam-
eter) arranged in three rows. Mice were left undisturbed
for 15 min under dim light. An observer blind to the
treatment counted the time spent in digging behaviour
and the number of marbles buried (at least two or third
buried in the sawdust). At the end of the test the animal
was removed to its own cage.
Western blotting synaptosome
Synaptic protein expression in prefrontal cortex was
assessed by western blotting analysis. The dissected pre-
frontal cortex tissue samples were lysed in Syn-PER Syn-
aptic Protein Extraction Reagent (Thermoscientific,
USA) (10 ml of Syn-PER Reagent per gram of tissue), in
order to isolate synaptosomes. Lysis buffer contained a
cocktail of phosphatase and proteinase inhibitors, Halt
Protease Inhibitor Cocktail (Thermoscientific, USA),
added immediately before use to avoid proteins degrad-
ation. Homogenization was carried out by mean dounce
tissue grinder on ice and homogenate was centrifuged at
1200×g for 10 min at 4 °C. The pellet was removed and
supernatant was centrifuged at 15000×g for 20 min at 4 °C.
After removing supernatant containing cytosolic fraction,
synaptosome pellet was suspended adding 1–2 ml of Syn-
PER Reagent per gram of sample. Protein concentration
in each sample was determined using Bradford assay and
equal amounts of total proteins were loaded onto 10 %
polyacrylamide gel for Psd-95, Shank1, mGluR5, mGluR7,
NR2a and b, Trkb, 15 % polyacrylamide gel for Homer1a
and Homer1b. Proteins were separated by SDS-PAGE and
transferred to nitrocellulose blotting membranes (GE
Healthcare, UK). Following blocking in buffer solution in-
cluding 5 % milk and 0.1 % Tween-20 in TBS (Tris HCl
25 mM, NaCl 137 mM), the membranes were immuno-
blotted with the following primary antibodies: Homer1a
(1:200; Santa Cruz Biotechnology), Homer1b (1:1000,
Santa Cruz Biotechnology), Psd95 (1:1000, Santa Cruz
Biotechnology), Shank1 (1:1000, Santa Cruz Biotechnol-
ogy), mGluR5 (1:1000, Santa Cruz Biotechnology), NR2a
(1:1000, Santa Cruz Biotechnology), NR2b (1:1000, Santa
Cruz Biotechnology), Trkb (1:1000, Santa Cruz Biotech-
nology). Then blots were incubated in species-appropriate
horseradish peroxidase-conjugated secondary antibodies
(1:2000, Santa Cruz Biotechnology) and proteins of
interest visualized by ECL detection (LiteAblot extend,
Euroclone) at molecular weight target. Quantification of
the bands intensity on scanned filters was achieved by
Quantity one analysis software (Bio-Rad, USA). Back-
ground value was subtracted to minimize variability across
membranes and each lane was normalized for the corre-
sponding actin value for variation in loading and transfer.
Data were analyzed by one-way ANOVA followed by
Turkey’s post-hoc test (level of significance p < 0.05). Data
were expressed as percentage of the mean of controls.
Statistical analyses were performed with StatView software
(version 5.0.1.0; SAS Institute).
Western blotting tissue
After protein determination by Bio-Rad Protein Assay
kit (Bio-Rad), equal amounts of total proteins (30 μg) for
each prefrontal cortex sample were loaded onto 10 %
polyacrylamide gels. Proteins were separated by SDS-
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PAGE and transferred overnight to membranes (Immo-
bilon PVDF Membrane, Millipore). The membranes
were immunoblotted overnight using selective antibodies
against BDNF (diluted 1:500, Santa Cruz Biotechnology,
Dallas, Texas), pSer473-Akt1, pSer235/236-S6, pSer-240/
244-S6 (each diluted 1:500, Cell Signaling Technology,
Beverly, MA). Blots were then incubated with appropriate
horseradish peroxidase-conjugated secondary antibody
and target proteins were visualized by ECL detection (GE
Healthcare), followed by quantification through Quantity
One software (Bio-Rad). Antibodies against Akt1 and S6
(both diluted 1:500, Cell Signaling Technology, Beverly,
MA), that are not phosphorylation state-specific were used
to estimate the total amount of proteins. All optical dens-
ity values were normalized using an antibody against
GAPDH (1:5000, Santa Cruz Biotechnology, Dallas,
Texas). Blots were then incubated in horseradish
peroxidase-conjugated secondary antibodies and target
proteins visualized by ECL detection (Pierce, Rockford,
IL), followed by quantification by Quantity One soft-
ware (Biorad). Normalized values were averaged and
used for statistical comparisons performed by one-way
ANOVA, followed by Turkey’s post-hoc test .
Cell cultures
Cortices of 17 days embryonic (E-17) mice were prelieved,
dissected carefully in ice, typsinized in 0.25 % Trypsin-
EDTA for 20 min. Tissues were centerfuged (2000 rpm)
for 1 min and filtered. Cells were seeded in Poly D-Lysine-
overnight pre-treated multiwells in serum free medium
(Neurobasal Medium+ 2 % B27 growth factor). Cells were
left to grow by changing half of medium every 3 days and
then they were treated at 14 DIV.
Cultured neurons western blotting
Total lysates from neuron cultures obtained through RIPA
buffer lysis were analyzed by western blot experiment after
treatment with PEA (100 nM, 24 h). Denaturated protein
(50 μg) was loaded on 10 % polyacrilamide gel and trans-
ferred on a Polyvinylidene Fluoride (PVDF) membrane
incubated overnight at 4 °C with the horseradish peroxid-
ase conjugated antibodies: goat polyclonal anti-mGluR5
(1:500; Santa Cruz Biothecnology), rabbit polyclonal anti-
Nr2b (1:500; Abcam), goat polyclonal anti-NR2a (1:1000;
Santa Cruz Biothecnology), and then with the relative sec-
ondary antibody for 1 h. Reactive bands were visualized
on a X-ray film. Whereas the same membrane trip was
used for revealing the expression of more than one protein
of interest, a mild stripping at 60 °C for 10 min was done.
Monoclonal anti-β-tubulin antibody (1:1000; Sigma) was
used as housekeeping protein to check for identical pro-
tein loading. Images were captured, stored, and analyzed
with the Quantity One software (BioRad, Hercules, CA).
In vivo single unit extracellular recordings
Mice for electrophysiological recordings were anaesthe-
tized with pentobarbital (50 mg/kg, i.p.) and placed in a
stereotaxic device (David Kopf Instruments, Tujunga,
CA). Body temperature was maintained at 37 ° C with a
temperature-controlled heating pad. In all surgical prep-
arations, the scalp was incised and holes were drilled in
the skull overlying the site of recording, medial pre-
frontal cortex (AP: +1–2.9, L: 0.2–0.3 from bregma and
V: 1.2–3 mm below dura) and contralateral (right) with
respect to the nerve insult (left). Anaesthesia was main-
tained with a constant continuous infusion of propofol
(5–10 mg/kg/h, i.v.). A glass-insulated tungsten filament
electrode (3–5 MΏ) (FHC Frederick Haer & Co., ME)
was stereotaxically lowered into the mPFC and the re-
corded signals were amplified and displayed on a digital
storage oscilloscope to ensure that the unit under study
was unambiguously discriminated throughout the ex-
periment. Signals were processed by an interface CED
1401 (Cambridge Electronic Design Ltd., UK) and ana-
lyzed through Spike2 software (CED, version 4) to create
peristimulus rate histograms online and to store and
analyze digital records of single-unit activity off-line.
Configuration, shape, and height of the recorded action
potentials were monitored and recorded continuously.
Neurons showed a cluster of spikes with an increased
frequency showing typically a Gaussian pattern of distri-
bution after stimulation. We measured the duration of
the excitation (in seconds) as the period of the increased
firing activity which exceeds the average baseline value
+2 standard deviations (SDs). Moreover, we measured
the the onset of excitation (in milliseconds) which was
considered as the time from the application of the stimu-
lus (artifact) to the first-evoked spike which exceeds the
average baseline value +2 SD. Moreover, the EAP slope,
indicating rate of activation of synaptic receptors, was
used for the evaluation of the efficacy of synaptic trans-
mission. Electrophysiolgical evaluations were performed in
the following groups of mice (n = 10): 1) sham mice; 2) 15
or 30 days SNI mice.
Microdialysis
Microdialysis experiments were performed in awake
and freely moving mice. In brief, mice were anaesthe-
tized and stereotaxically implanted with concentric mi-
crodialysis probes into the mPFC using coordinates:
AP: 1.4–1.8 mm, L: 0.3–05 mm from bregma and V:
3.0 mm below the dura. Microdialysis probes were con-
structed with 22G (0.41 mm I.D., 0.7 mm O.D.) stain-
less steel tubing: inlet and outlet cannulae (0.04 mm
I.D., 0.14 mm O.D.) consisted of fused silica tubing.
The probe had a tubular dialysis membrane (Enka AG,
Wuppertal, Germany) 1.3 mm in length. Following a
recovery period of 24 h, dialysis was commenced with
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ACSF (NaCl 147 mM, CaCl2 2.2, KCl 4 mM; pH 7.2)
perfused at a rate of 1 μL/min by a Harvard Apparatus
infusion pump. Following a 60-min equilibration period,
12 consecutive 30-min dialysate samples were collected.
At the end of experiments, mice were anaesthetized and
their brains perfused fixed via the left cardiac ventricle
with heparinised paraformaldehyde saline (4 %). Brains
were dissected out and fixed in a 10 % formaldehyde solu-
tion for 2 days. The brain were cut in 40-μm thick slices
and observed under a light microscope to identify the
probe locations. Dialysates were analyzed through an high
performance liquid chromatography method. The system
comprised a Varian ternary pump (mod. 9010), a C18
reverse-phase column, a Varian refrigerated autoinjector
(mod. 9100), a Varian fluorimetric detector. Dialysates
were precolumn derivatized with Opthaldialdehyde (10 μl
dialysate + 10 μl o-pthaldialdehyde) and amino acid conju-
gates resolved using a gradient separation. The mobile
phase consisted of 2 components: 1) 0.2 M sodium phos-
phates buffer (pH 5.8), 0.1 M citric acid (pH 5.8) and 2)
90 % acetonitrile, 10 % distilled water. Additionally, to de-
termine the amount of area peak due to D-Aspartate, a
parallel sample was incubated with 2 ml of purified D-Asp
Oxidase for 15 min at 37 °C and chromatographed as
above. The total disappearance or the reduction of area
peak corresponding to D-Asp elution peak confirmed the
presence of D-Asp and gave the exact amount of the con-
tent of D-Asp. A typical analysis is represented in Fig. 5.
Data were collected by a Dell Corporation PC system 310
interfaced by Varian Star 6.2 control data and acquisition
software. The data were expressed as mean of five samples
for each mice.
Measurement of N-acylethanolamines levels (PEA and OEA)
The extraction, purification and quantification of N-
acylethanolamines from tissues has been performed as
previously described [32]. Briefly, tissues were dounce-
homogenized and extracted with chloroform/methanol/
Tris–HCl 50 mmol/l pH 7.5 (2:1:1, vol/vol) containing
internal standards [2H]4 PEA and [2H]2 OEA 50 pmol
each). The lipid-containing organic phase was dried
down, weighed, and pre-purified by open-bed chroma-
tography on silica gel. Fractions were obtained by elut-
ing the column with 99:1, 90:10 and 50:50 (v/v)
chloroform/methanol. The 90:10 fraction was used for
PEA and OEA quantification by liquid chromatogra-
phy—atmospheric pressure chemical ionization—mass
spectrometry by using a Shimadzu high-performance li-
quid chromatography apparatus (LC-10ADVP) coupled
to a Shimadzu (LCMS-2020) quadrupole mass spec-
trometry via a Shimadzu atmospheric pressure chem-
ical ionization interface as previously described [32[.
LC analysis was performed in the isocratic mode using
a Discovery C18 column (15 cm × 4.6 mm, 5 μm) and
methanol/water/acetic acid (85:15:1 by vol.) as mobile
phase with a flow rate of 1 ml/min. The amounts of
componds in tissues, quantified by isotope dilution
with the abovementioned deuterated standards, are
expressed as pmol/mg.
Immunohistochemistry and immunofluorescence
Under pentobarbital anesthesia (50 mg/kg, i.p.), animals
were transcardially perfused with saline solution
followed by 4 % paraformaldehyde in 0.1 M phosphate
buffer. The brains were excised, post fixed for 3 h in
the perfusion fixative, cryoprotected for 72 h in 30 %
sucrose in 0.1 M phosphate buffer, and frozen in Opti-
mal cutting temperature (O.C.T.) embedding com-
pound. Transverse sections (20 μm) were cut using a
cryostat and thaw-mounted onto glass slides. Slides
were incubated overnight with primary antibody solu-
tions for the microglial cell marker Iba-1 (rabbit anti-
ionized calcium binding adapter molecule-1; 1:1000;
Wako Chemicals, Germany). Possible non-specific la-
beling of mouse secondary antibody was detected by
using secondary antibody alone. Following incubation,
sections were washed and incubated for 2 h with sec-
ondary antibody solution (donkey anti-rabbit Alexa
FluorTM 488; 1:1000; Molecular Probes, USA). Slides
were washed, coverslipped with Vectashield mounting
medium (Vector Laboratories, USA), and visualized
under a Leica fluorescence microscope. The number of
cells positive for Iba-1 was determined within a box
measuring 2×104 μm2 that was placed in the m-PFC.
Six sections were assessed from one animal and three
animals were used for each group. To avoid cell over-
counting, only DAPI-counterstained cells were considered
as positive profiles. Iba-1 -positive cells were identified as
resting (with small somata bearing long, thin and ramified
processes), activated microglia (with hypertrophy together
with retraction of processes to a length shorter than the
diameter of the somata) or hyper-branched microglia
(with increased number of branches).
Results
Effect of systemic treatment with PEA (or OEA) on pain
behaviour
Spared nerve injury (SNI) of the sciatic nerve de-
creased the ipsilateral paw nociceptive thresholds to
mechanical (4 g ± 0.1) or thermal stimuli (4.3 s ± 0.2)
(Fig. 1a and b). No change was observed in mechanical
or thermal thresholds in the contralateral paw of SNI
or sham-operated mice. We found that repeated PEA
treatment (10 mg/kg i.p., once per day) significantly
increased both the thermal and mechanical thresholds
in SNI mice (7.8 s ± 0.5 and 7.4 g ± 0.4, respectively)
30 days after injury. Moreover, no changes in pain
thresholds of PEA-treated sham animals were
Guida et al. Molecular Brain  (2015) 8:47 Page 5 of 15
observed (not shown). Similarly to PEA, repeated
OEA treatment (10 mg/kg i.p., once per day) signifi-
cantly increased mechanical threshold in SNI mice
(5.96 ± 0.2 and 5.82 ± 0.19, respectively) at 15 and
30 days after the nerve injury (Fig. 1c). Whilist, no
change in pain thresholds of OEA-treated sham ani-
mals was observed (not shown).
Effect of systemic treatment with PEA on tail suspension
immobility
Neuropathic mice show an increased duration of immo-
bility during tail suspension 30 days after surgery. In-
deed, the time of immobility was significantly higher in
the SNI mice that received vehicle as compared to
vehicle-treated sham animals (133.2 s ± 13.2 and 54.4 s ±
5.6, respectively). However, the repeated PEA treatment
(10 mg/kg i.p., once per day) significantly reduced the
time of immobility (48.5 s ± 7.4). PEA treatment did not
change the time of immobility in sham mice (Fig. 1d).
Effect of systemic treatment with PEA on the object
recognition test
In the object recognition test SNI mice that received
chronic vehicle administration showed a significant
decrease in the recognition index (41.9 ± 1.2) as com-
pared to the sham animals (67.10 ± 2.90) (Fig. 1e). The
repeated PEA treatment (10 mg/kg i.p., once per day)
significantly increased the recognition index in the SNI
mice (65.0 ± 3.7), but not in the sham mice (74.9 ± 3.1).
Effect of systemic treatment with PEA on marble-burying
test
During the 15 min marble burying task, vehicle-treated
sham and SNI mice significantly differed in the number
of buried marbles 30 days after surgery, which was 6.6 ±
0.53 and 11.8 ± 0.37 respectively in sham and SNI mice.
In addition, the number of digging events was signifi-
cantly higher in SNI mice (431.4 ± 67.7) as compared to
sham mice (84.40 ± 4.7) (Fig. 1e). We observed that the
number of buried marbles (10.2 ± 0.41) and the number
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Fig. 1 Effects of PEA (or OEA) on mechanical allodynia (a and c), on thermal hyperalgesia (b), on duration of immobility in the tail suspension (d),
on the index of recognition in the novel object recognition task (e) and on on the number of digging events in the marble burying (f) in sham
and SNI mice. Behaviours were determined 30 days after SNI or sham surgery, in presence of vehicle (Pluronic F-68, 5 % v/v) or PEA or OEA
(10 mg/kg). Each point represents the mean ± standard error of the mean (S.E.M) of 10–12 mice. ° and * indicate significant differences compared
to sham/vehicle and SNI/vehicle, respectively. P < 0.05 was considered statistically significant
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of digging events was not changed following PEA treat-
ment, in both sham and SNI mice (Fig. 1f ).
Effect of SNI on acylethanolamines (PEA and OEA) in the
mPFC
We next measured PEA and OEA level in the m-PFC
of sham or SNI mice. We found that SNI increased
PEA level (2.2 ± 0.3 pmol/mg) 15 days after the nerve
injury, as compared with sham animals (0.9 ± 0.1 pmol/
mg) (P < 0.05). However, endogenous PEA amount re-
sulted normalized 30 days post SNI (1.1 ± 0.1 pmol/
mg). The same surgical procedure did not affect OEA
levels (0.8 ± 0.1 pmol/mg) in the mPFC.
Effect of PEA on post-synaptic proteins expression in
m-PFC synaptosomes in SNI mice
Western blotting were carried on m-PFC synaptosomes
fractions obtained from sham or neuropathic mice in
the presence of vehicle or PEA (10 mg/kg, once per
day). We found that 30 days of SNI induced significant
changes in mGluR5, NMDAR-NR2b subunit and in the
inducible homolog Homer 1a (Homer 1a) protein ex-
pression levels (Fig. 2). In particular, the mGluR5 pro-
tein levels resulted significantly increased in SNI mice,
as well as, in PEA-treated SNI or sham animals (Fig. 2a).
The SNI procedure also led to a significant increase in
NR2b protein expression as compared with sham mice
(Fig. 2c). This effect was completely reversed in SNI
mice receiving PEA repeated treatment, and, interest-
ingly, PEA also reduced NR2b expression in physio-
logical condition (sham mice) (Fig. 2c). No changes in
the NR2a subunit protein levels were observed (Fig. 2b).
Moreover, SNI mice showed increased the Homer1a
protein levels, which resulted significantly reduced in
the PEA-treated animals (Fig. 3c). In contrast, the levels
of Homer1b, which is constitutively expressed in the
brain, did not change in neuropathy condition (Fig. 3b).
Finally, PEA caused a decrease of post-synaptic density
protein-95 (PSD-95) levels, which instead resulted un-
changed in SNI mice (Fig. 3a). Any change in Shank-1,
the protein bridge between NMDAR and other scaf-
folding proteins, in sham or SNI mice was observed
(Fig. 3b).
Effect of PEA on BDNF/TrkB/Akt signalling in m-PFC of
SNI mice
To investigate possible changes in the cortical brain-
derived neurotrophic factor (BDNF) regulation, we
Fig. 2 Expression levels of postsynaptic proteins, measured using Western blot analysis, in synaptosomes from the mPFC of sham and SNI
30 days after surgery, in presence of vehicle or PEA (10 mg/kg). “a”, “b” and “c” show the protein expressions of mGluR5, Nr2a and Nr2b,
respectively, normalized to β-Actin. Data are represented as a mean ± SEM of 6 mice per group. ° and * indicate significant differences compared
to sham/vehicle and SNI/vehicle, respectively P < 0.05 was considered statistically significant. ANOVA, post hoc Tukey
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analysed the BDNF and its conjugate tropomyosin re-
ceptor kinase B (TrkB) level expression in the mPFC of
SNI mice. Our data revealed a decrease in BDNF levels of
SNI mice, as compared with sham animals. PEA treatment
(10 mg/kg, once per day) significantly prevented this effect
(Fig. 4a). Conversely, SNI mice showed increased TrkB
expression which was significantly restored by PEA treat-
ment (Fig. 4b). Finally, PEA was effective in restoring
the protein level of the 70-kDa ribosomal S6 kinase
(pS6K) and the serine/threonine kinase (Akt) which re-
sulted increased in SNI mice. Interestingly, PEA also
increased Akt expression in physiological condition
(sham mice) (Fig. 4c and d).
Effect of single microinjection of PEA (or OEA) in mPFC of
SNI mice
Single microinjection of PEA or OEA (6 nmol/mouse)
into the mPFC led to a reduction of mechanical allodynia
in SNI mice 30 days post injury. In particular, we observed
that single PEA microinjection decreased mechanical
threshold with maximum effect at 75 min post-drug
(6.2 g ± 0.26) with respect to SNI/vehicle mice (3.5 g ± 0.4)
(Fig. 5a). On the other hand, OEA treatment immediately
and transiently reduced mechanical allodynia (6.4 g ± 0.54)
which lasted up to 30 min post injection (Fig. 5a). At the
dose tested, PEA or OEA did not change the pain thresh-
olds in both sham or SNI animals (not shown).
Effect of PEA on post-synaptic proteins expression in cul-
tured cortical neurons
To assess a possible specific effect on neuronal cells,
we applied PEA in cultured neurons obtained from cor-
tices of pups mice. We observed that PEA exposure
(100 nM, 24) was capable to modify part of the post-
synaptic proteins expression that we found changed in
PEA-treated animals. In particular, we found an in-
crease in the expression level of mGluR5 and in the
inducible NMDA-NR2b subunit as compared with not
treated cells, while no changes in the NR2a levels were
observed. (Fig. 5b, c and d).
Electrophysiological characterization of mechanical
stimulation-evoked responses of mPFC (+) neurons in
sham, SNI 15 days and SNI 30 days mice
Single-unit extracellular recording in anesthetized mouse
was made from individual neurons in the mPFC. The
slow spontaneous firing rate of about 0.1–1.5 ± 0.4
spikes/s from recorded neurons was consistent with
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presumed pyramidal cells [33, 34]. (Fig. 6a) rather than
fast-spiking interneurons, the latter having a higher
baseline firing rate (>10 Hz) and narrower spike wave-
form (<300 μs) [35, 36]. We investigated the mPFC neu-
rons with ongoing activity that responded with
excitation [mPFC(+)] to mechanical stimulation by von
Frey filaments with bending force of 97.8 mN (noxious
stimulation) for 2 s [37]. Neurons that displayed no
change in firing in response to stimulation were dis-
carded. The duration and the onset of excitation were
1.67 ± 0.16 s and 1433 ± 94 ms, respectively (Fig. 6c and d),
while the value of slope was −4.22 ± 0.67 mV/ms (Fig. 6e).
14 days-SNI mice showed an increased ongoing activity
[1.31 ± 0.08 spikes/s; P < 0.001], as compared to sham ani-
mals. Moreover, we also observed an increase in the
duration of the excitation [5.94 ± 0.57 s; P < 0.01] (Fig. 6d)
and in the EAP slopes [−9.22 ± 0.48 mV/ms] (Fig. 6e),
while the onset was reduced [193.6 ± 77.18 ms; P < 0.01]
(Fig. 6e). Intriguingly, the ongoing cell activity, as well as,
the onset of excitation resulted normalized in 30 days SNI
mice [0.42 ± 0.17 spikes/s; P < 0.01 and 1486 ± 370.2 ms;
P < 0.05, respectively] (Fig. 6c and e). However, the
duration of the excitation [5.32 ± 0.93 s, P < 0.01 versus
sham] and the EAP slopes [−8.77 ± 0.22 mV/ms, res-
pectively; P < 0.001 versus sham] did not show any dif-
ference as compared with 15 days-SNI mice.
PEA effects on amino acids release in the mPFC of SNI
mice
In vivo microdialysis methodology was used to assess the
amino acids contents in the m-PFC of 30 days SNI mice.
HPLC analysis revealed an important increase of extra-
cellular D-Aspartate (D-Asp) levels in the mPFC of
neuropathic mice as compared with sham animals
(Fig. 7a). Accordingly, the D-Asp precursor, L-Aspartate
(L-Asp), was also increased (not shown). On the con-
trary, glutamate levels resulted significantly decreased in
SNI mice, but PEA was not able to revert this effect.
Interestingly, we found that PEA also reduced glutamate
levels in the mPFC of sham mice (Fig. 7b). The same
SNI 15 dd
SNI 30 dd
shamhind paw 
pinch
A
D
F
***
°°°
B
** **
C
°°
** *** ***
E
Fig. 6 The figure shows different parameters of mechanical stimulus-evoked excitation in sham and SNI mice, 15 and 30 days (dd) after the
induction of SNI. “a” shows schematic illustration of mechanical stimulation applied to the hind paw (contralateral to the mPFC). “b”, “c” and “d”
show the mean ± standard error of the spontaneous activity, the duration and the onset of excitation in the different groups of mice (n = 10). “e”
shows relative EAP slopes.* indicates statistically significant difference versus sham mice. ° indicates significant difference versus SNI 15 days mice.
P < 0.05 has been considered as value of significance. The double symbol indicates P < 0.01 and the triple symbol indicates P < 0.001. “f” shows
representative spike-waveform of mPFC (+) neurons recorded in sham, SNI 15 days and SNI 30 days mice
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surgical procedure did not affect dialysate GABA level
(not shown).
Effect of systemic PEA treatment on m-PFC microglia
activation
To investigate the potential involvement of supraspinal
microglia in mediated-PEA effects, we evaluated possible
changes in cell morphology in the m-PFC of sham or
SNI mice in presence of vehicle or PEA (10 mg/kg, i.p.).
SNI did not change the number of both total or acti-
vated Iba-1 positive cells in the m-PFC of neuropathic
rodents accordingly with previous findings [38]. How-
ever, PEA-treated sham animals showed an increase of
the number of hyper-branched microglia with very long
ramified processes as compared with vehicle-treated ani-
mals (Additional file 1).
Discussion
Altered glutamate signalling strongly correlates with the
pathophysiological processes responsible for chronic
pain and development of neurological disorders. In
addition to pain sensory symptoms, glutamate-driven
neuro-psychological functioning is thought to be
affected by chronic pain, and a complex forebrain net-
work (the “pain matrix”) may represent the substrate for
negative affective states (fear, anxiety, and depression)
associated with pathological pain [39, 40].
Over the last few decades, accumulating evidence has
shown that pathological pain induces glutamatergic sig-
nalling enhancement in the dorsal horn of the spinal
cord [41]. This excitatory deregulation is responsible for
the spinal wind-up phenomenon and, in turn, for the
maintenance of tactile allodynia and hyperalgesia [42].
Conversely, changes in the glutamatergic synapses in
forebrain areas linked with allodynia and emotional
aspects of chronic pain remain poorly explored. Others
and we have demonstrated that enhanced cortical glu-
tamate level may contribute to central sensitization
during neuropathic pain [1, 8, 43]. In particular, we
showed that 7 days of SNI caused pain behaviour asso-
ciated with several changes in the prelimbic-infralimbic
cortices, including enhanced expression of the transient
receptor potential vanilloid type-1 (TRPV1) channel on
glutamatergic fibers, with a subsequent increase in
extracellular glutamate level [8]. In the present study,
we evaluated pain and neuropsychiatric behavioural
D
- A
S
P
L
-A
S
P
L
-G
L
U
0.0
0.5
1.0
1.5
Sham+veh Sham+PEA SNI+veh SNI+PEA
D
-A
sp
 r
el
ea
se
(p
m
ol
/1
0
μl
)
0
5
10
15
Sham+veh Sham+PEA SNI+veh SNI+PEA
G
lu
ta
m
at
e 
re
le
as
e
 (
pm
ol
/1
0
μl
)
A B
°
° °
°*
C D
D
-A
S
P
L
-A
S
P
L
-G
L
U
Fig. 7 Release of D-Aspartate (a) or glutamate (b) in sham or SNI mice 30 days after injury. The values of extracellular amino acids in the mPFC were
expressed as pmol in 10 μl of perfusate. Each point represents the mean ± S.E.M of 7–8 animals per group. P< 0.05 was considered statistically significant.
ANOVA, post hoc Tukey. “c” shows a typical HPLC determination of D-Asp, L-Asp and Glutamate in neuropathic mice. “d” shows the same sample as in A
after treatment with DDO. The peak corresponding to D-Asp disappears because of oxidation by DDO. The arrow shows the elution of D-Asp
Guida et al. Molecular Brain  (2015) 8:47 Page 11 of 15
changes associated with possible bio-molecular, mor-
phological and electrophysiological modifications in the
mPFC glutamate synapse at day 30th post-injury. In
particular, we quantitated synaptic proteins in the
mPFC-derived synaptosome to minimize contamination
by non-neural cell derived proteins. SNI mice showed
an increase in the expression level of mGluR5 and
NMDA-NR2b subunit. These synaptic maladaptive
changes in the post-synaptic membrane, similarly to
other chronic neuro-psychiatric diseases [44–46], may
critically occur following peripheral nerve injury [47].
Accordingly, our results show that expression level of
the synaptic scaffolding protein Homer1a (the inducible
post-synaptic component responsible for decreasing the
aggregation or clustering of the PSD proteins), was in-
creased in SNI animals, while the constitutive Homer1b
protein did not change in the same condition. Con-
versely, we observed that other post-synaptic signal
transduction components, such as Shank-1 and PSD-
95, which are involved in the pathophysiology of other
neurological disorders including schizophrenia [48],
were not modified in this model of neuropathic pain.
These findings suggest that long-term SNI state may
exert a Homer1a-regulated PSD changes that are con-
sistent with the 30 days SNI-induced excitatory synap-
tic functioning inpaired activity. In fact, even though at
30 days after SNI, animals showed superimposable allo-
dynia and hyperalgesia to the short-term neuropathy
(7 days SNI) animals, we observed a decreased - instead
of an increased as shown in 7 day SNI - mPFC glutam-
ate level when compared with sham mice. Accordingly,
by using single unit extracellular recordings in vivo, we
found that 30 days-neuropathic mice showed an overall
depressed activity of PLC pyramidal neurons, as compared
to 7 [8] or 15 days SNI, which instead proved enhanced
neuronal activity, as compared to sham animals. There-
fore, these findings indicate that long-term injury may be
responsible for hypofunctional glutamate signalling at the
supraspinal level and, possibly, of the pain-associated
negative affective states. Indeed, a fine-tuned change may
have occurred in the glutamate synapses since we found
here the extracellular levels of D-aspartic acid (D-Asp) sig-
nificantly enhanced in the mPFC of SNI mice. D-Asp may
play a role in synaptic plasticity-mediated processes, such
as memory, learning, and pain [49, 50], by acting as an
agonist on NMDA receptors through binding to each of
the GluN2 subunits [51, 52]. In this study, low level of D-
Asp was detectable in physiological conditions, while high
level was observed in the mPFC of 30 days-SNI animals.
Thus, a possible counterbalance of D-Asp may occur as a
consequence of dysregulation of glutamate level following
long lasting SNI, which in turn may drive changes in
receptor expression as a further adaptive responses. Intri-
guingly, while PEA reduced pain, as well as the pain-
associated affective behavioural changes, it failed to restore
the physiological glutamate levels, but normalized D-Asp
concentrations in the mPFC.
As we have shown previously [8], our results showed
no difference in mPFC GABA levels between sham-
operated and SNI animals. Although changes in GABA
levels were not appreciable in SNI-induced short or
long-term neuropathy, GABA homeostatic concentra-
tions were strongly preserved, possibly to counteract the
altered glutamatergic tone.
Similarly to humans, SNI animals remain oversensi-
tive to tactile and thermal stimuli months after injury,
with a late development of anxio-depressive syndrome.
In this study, animals at 30 days after injury showed
mechanical and thermal hypersensitivity, together with
depression-like behaviour, cognitive impairments, and
obsessive-compulsive-like activities. Daily treatment with
the acylethanolamide PEA (or OEA) reduced most of the
SNI-induced pain-related behaviours. Even though PEA is
effective in neuropathic symptoms in model of relatively
short lasting neuropathy (i.e. allodynia is measurable up to
15–20 days after chronic constriction injury of the sciatic
nerve, CCI model) [53, 54], we provide here the first evi-
dence that PEA (or OEA) also reduces pain symptoms in
a model of debilitating long lasting pain (the SNI model),
which is comparable to an advanced stage of neuropathy
in humans [55]. It has been shown that different experi-
mental pain models are accompanied by significant
changes in the tissue concentrations of analgesic endocan-
nabinoids and PEA [23]. We have previously shown that
endogenous PEA levels are down-regulated 7 days after
CCI induction in brainstem areas controlling pain, sug-
gesting a role of this acylethanolamide in the development
of hyperalgesia in neuropathic pain [23]. In fact, in the
current study we observed an increase of PEA levels in the
mPFC of 15 days-SNI mice, whilst it was normalized
30 days post nerve injury. All together, these observations
indicate that production of PEA might be an adaptive
response to neuropathic pain development aimed at coun-
teracting pain transmission or manteinance.
We observed here that PEA also reverted the depres-
sion and the impaired performances in discriminative
memory associated with long-term neuropathy; import-
antly, PEA did not affect stereotypical behaviours in the
marble burying test. The therapeutic failure of PEA in
this latter test, which was applied as an index of anxiety
and/or repetitive activity, might suggest that PEA does
not engage neural circuits (i.e. striatum) or neurotrans-
missions (i.e. serotonin or dopamine) shown to be im-
plicated in motor over-activity or obsessive-compulsive
disorders [56]. With regard to the resolution of pain
and depressive-like syndrome in SNI mice, PEA re-
versed the Homer1a and Nr2b over-expression in the
mPFC of these animals, but not that of mGluR5, which
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might be spared for the overall maintenance of the ex-
citatory synapses.
Compounds that are able to antagonize the Nr2b sub-
unit selectively are effective in reducing neuropathic
pain in animals and patients, by avoiding psychotomim-
etic effects, as well as motor deficits attributable to the
classical analgesics [57]. Moreover, selective Nr2b recep-
tor antagonists produce antidepressant effects (ketamine
like) in rodent models [58] and in human subjects [59].
In fact, the crucial role of Nr2b in the the rapid actions
of ketamine associated with the downstream regulation
of mammalian targets of rapamycin (m-TOR) signalling
and BDNF release has been demonstrated [60].
Indeed, in this study, PEA reduced NR2b expression
in both sham and neuropathic mice. This finding may
indicate a further mechanism of PEA action in order to
explain its anti-neuropathic effect as well as its effective-
ness in alleviating anxiety/depression-like behaviours. In
fact, since the nuclear peroxisome proliferator-activated
receptor-α (PPAR-α) has been suggested as its molecular
target [61], we can speculate that a 15 days treatment
with PEA could be responsible, at least in part, for the
Nr2b down-regulation through a genomic mechanism
and adds more complexity and value to the so called
“entourage effect” of PEA [62].
It is also worthy of note that, the m-TOR signalling,
including phospho-Akt and phospho-S6, involved in
cells survival, proliferation, and protein synthesis, were
up-regulated dramatically in SNI mice and normalized
by PEA treatment. Moreover, the SNI-induced reduction
of BDNF and the concurrent enhancement of TrkB
levels were restored by PEA. In fact, changes in BDNF
and subsequent alterations in synaptic plasticity have
been shown to contribute to both pain and depression
[63, 64]. Intriguingly, the BDNF release by microglia
cells in the dorsal horn of spinal cord, has been shown
to be associated with the development of tactile allody-
nia by shifting in neuronal anion gradient in the lamina
one nociceptive neurons [65]. Despite the effect of the in-
creased BDNF release in the spinal cord, that also involves
the P2X4-mediated activation of microglia, the few data
available at supraspinal level, showed that neuropathic
pain is associated with a reduction of the BDNF levels in
the cingulate cortex (ACC) [63, 64], according with our
data in the mPFC. These changes in supraspinal BDNF
level could be related to the depressive-like behaviour ra-
ther then directely correlated to the development of tactile
allodynia.
These data provide evidence that SNI-associated neuro-
psychiatric behaviours, particularly the anxious-depressive
syndrome, may be related to molecular changes of factors
such as BDNF involved in the well-being of neurons.
Whether the supraspinal molecular changes are related to
peripheral and/or circulating factors (i.e. hormons,
cytokines) or driven by a specific brain cell-network (i.e.
neurons-astrocytes-microglia) remains unclear. Indeed, this
study confirms that supraspinal (at least cortical) microglia
are not affected by peripheral nerve injury [38]. However,
we observed that PEA induces an increase of hyper-
ramified microglia, possibly associated with an alterna-
tive activated (non phagocytic) phenotype indicative of
an hyper-surveillance state. Moreover, we show that,
although it does not alter behaviour in selected tasks,
PEA is able to physiologically regulate the substrates
production, as well as, neurotransmitters release in
brain areas controlling not only pain, but several
neurological processes, including cognition, memory
and reward. Thus, we can not exclude that PEA may
play a physiological role in different neuropsychological
functions.
All these results (behaviors and synaptic changes in
mPFC) could be simply due to the PEA’s effects in spinal
cord or periphery. The possible role of PEA or OEA in
decreasing allodynia by also acting within the PL-IL cor-
tex was here suggested by the fact that a single direct
microinjection in those forebrain areas exerted a signifi-
cant anti-allodynic effect. Interestingly, we observed that
while OEA microinjection induced a rapid and transient
analgesia, probably due to activation/desensitization of
capsaicin-sensitive TRPV1 channels [65, 66] PEA exerted
a delayed analgesic effects (50–60 min post-injection).
This difference suggests that PEA, unlike OEA, might
promote via PPARa activation the neo-synthesis of pro-
teins aimed at counteracting pain perception.
Moreover, in order to further clarify the effect of PEA
on neurons, we performed a set of in vitro experiments.
We found that 24 h PEA exposure affected synaptic
omeostasis in neuron primary cultures by modifying the
expression level of Nr2b and mGluR5 receptors, even
though a different modulation of Nr2b, as compared
with in vivo PEA treatment, was observed. Similar dis-
crepancy already has been observed with antidepressant
drugs and might be consequence of differences in dos-
age, time drug exposure, brain area used or cell cultures
[67–69]. Nevertheless, it remains unknown whether the
neuropsychiatric changes, including the brain molecular
changes, represent effects driven by peripheral injury or
prolonged maintenance of the tactile allodynia or both.
Thus, based on these findings, we can not roule out that,
because of the overall peripheral anti-inflammatory
effect of PEA, a “secondary” ameliorating action may be
also observed in the mPFC.
Conclusions
In conclusion, our results demonstrate that long-term per-
ipheral nerve injury causes phenotypic changes in pyram-
idal neurons of mPFC with a remodeling of the glutamate
synapses and modification in the expression of synaptic
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density molecules. Moreover, we showed that chronic
PEA treatment reduced pain and related anxio-depressive
behaviour by in part restoring glutamatergic synapse
homeostasis. Given the potential role of the mPFC in pain
mechanisms, our findings may provide novel insights into
neuropathic pain processes and indicate PEA as a new
pharmacological tool to treat neuropathic pain and the re-
lated negative affective states.
Additional file
Additional file 1: Iba-1 immunoreactivity (Iba-1-ir) is shown in the
m-PFC of sham or SNI mice (30 days after injury) following PEA
(10 mg/kg, i.p.) or vehicle treatment (A). Quantitative analysis of total,
or activated or hyperbranched, is shown in “B”. Data are expressed as
mean ± S.E.M of 3 mice per group. * indicates significant differences
compared to sham/vehicle. P < 0.05 was considered statistically
significant. ANOVA, post hoc Tukey. (PPT 1605 kb)
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